| Literature DB >> 33859290 |
Isabella Batten1, Mark W Robinson2, Arthur White3, Cathal Walsh4, Barbara Fazekas5, Jason Wyse3, Antonia Buettner6, Suzanne D'Arcy6, Emily Greenan7,8, Conor C Murphy7,8, Zoe Wigston9,10, Joan Ní Gabhann-Dromgoole7,11, Edward M Vital9,10, Mark A Little6, Nollaig M Bourke12.
Abstract
Type I interferon (IFN) dysregulation is a major contributory factor in the development of several autoimmune diseases, termed type I interferonopathies, and is thought to be the pathogenic link with chronic inflammation in these conditions. Anti-neutrophil cytoplasmic antibody (ANCA)-Associated Vasculitis (AAV) is an autoimmune disease characterised by necrotising inflammation of small blood vessels. The underlying biology of AAV is not well understood, however several studies have noted abnormalities in type I IFN responses. We hypothesised that type I IFN responses are systemically dysregulated in AAV, consistent with features of a type I interferonopathy. To investigate this, we measured the expression of seven interferon regulated genes (IRGs) (ISG15, SIGLEC1, STAT1, RSAD2, IFI27, IFI44L and IFIT1) in peripheral blood samples, as well as three type I IFN regulated proteins (CXCL10, MCP-1 and CCL19) in serum samples from AAV patients, healthy controls and disease controls. We found no difference in type I IFN regulated gene or protein expression between AAV patients and healthy controls. Furthermore, IRG and IFN regulated protein expression did not correlate with clinical measurements of disease activity in AAV patients. Thus, we conclude that systemic type I IFN responses are not key drivers of AAV pathogenesis and AAV should not be considered a type I interferonopathy.Entities:
Year: 2021 PMID: 33859290 DOI: 10.1038/s41598-021-87760-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379